BRCA2 and familial pancreatic carcinoma: This notion has, however, recently been questioned with data demonstrating that loss of Brca2 heterozygosity is not a required event in murine models of familial pancreatic cancer and, for human carriers of the BRCA2 999del5 mutation, that loss of heterozygosity (LOH) might not be needed to promote carcinogenesis in the pancreas [7].